It is now known that treatments targeting tumor necrosis factor alpha (TNFα) and methotrexate, which are used for their immunosuppressive effect to fight chronic inflammatory diseases (rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus) [5,6] or transplant rejection, predispose the organism to oncogenesis [7]. This evidence concerns the gene TNF and inflammatory bowel disease.